Key Points
- CEO Paul Badawi sold 29,244 shares on April 1 at an average price of $3.70 for $108,202.80, reducing his stake by 0.47% to 6,151,156 shares (valued at about $22.76M).
- Badawi also executed earlier insider sales this year (22,362 shares on Jan 16 at $6.62 and 11,870 shares on Jan 6 at $7.48), indicating a pattern of multiple disposals.
- Sight Sciences trades near $3.52 with a market cap of ~$190.1M, negative EPS but a slight quarterly EPS beat, and a consensus analyst target of $8.31 amid mixed Buy/Hold/Sell ratings.
Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) EVP Brenton Taylor sold 2,869 shares of Sight Sciences stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $3.70, for a total value of $10,615.30. Following the transaction, the executive vice president directly owned 267,807 shares of the company's stock, valued at $990,885.90. This trade represents a 1.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Brenton Taylor also recently made the following trade(s):
- On Tuesday, January 6th, Brenton Taylor sold 619 shares of Sight Sciences stock. The stock was sold at an average price of $7.48, for a total transaction of $4,630.12.
Sight Sciences Price Performance
Shares of NASDAQ SGHT opened at $3.52 on Friday. The company has a current ratio of 10.22, a quick ratio of 9.52 and a debt-to-equity ratio of 0.63. The company's 50-day moving average price is $4.82 and its 200 day moving average price is $5.73. Sight Sciences, Inc. has a 52 week low of $2.03 and a 52 week high of $9.24. The stock has a market cap of $190.12 million, a price-to-earnings ratio of -4.69 and a beta of 2.50.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its earnings results on Wednesday, March 4th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.07. Sight Sciences had a negative net margin of 49.67% and a negative return on equity of 55.72%. The company had revenue of $20.39 million during the quarter, compared to analysts' expectations of $20.35 million. As a group, research analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research firms recently issued reports on SGHT. Stifel Nicolaus upped their target price on Sight Sciences from $6.00 to $8.00 and gave the company a "buy" rating in a research note on Monday, March 2nd. Citigroup cut their price target on Sight Sciences from $9.10 to $6.50 and set a "neutral" rating for the company in a report on Friday, March 6th. William Blair restated an "outperform" rating on shares of Sight Sciences in a research report on Thursday, March 5th. UBS Group decreased their price objective on Sight Sciences from $12.00 to $11.00 and set a "buy" rating on the stock in a research note on Friday, March 6th. Finally, Piper Sandler set a $9.00 price objective on Sight Sciences in a research report on Monday, January 5th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $8.31.
View Our Latest Stock Analysis on SGHT
Institutional Investors Weigh In On Sight Sciences
Several hedge funds have recently modified their holdings of SGHT. AQR Capital Management LLC purchased a new stake in Sight Sciences in the first quarter valued at approximately $128,000. Strs Ohio purchased a new position in Sight Sciences during the first quarter worth approximately $158,000. Rhumbline Advisers raised its stake in Sight Sciences by 9.5% during the first quarter. Rhumbline Advisers now owns 49,797 shares of the company's stock worth $120,000 after purchasing an additional 4,319 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Sight Sciences by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 845,776 shares of the company's stock valued at $3,494,000 after purchasing an additional 43,791 shares during the last quarter. Finally, Intech Investment Management LLC grew its stake in shares of Sight Sciences by 26.2% during the 2nd quarter. Intech Investment Management LLC now owns 25,366 shares of the company's stock valued at $105,000 after buying an additional 5,261 shares during the period. 55.51% of the stock is owned by institutional investors and hedge funds.
Sight Sciences Company Profile
(
Get Free Report)
Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.
Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
